A NEW AI (Artificial Intelligence) model, AlphaFold3, has excited the scientific community. Developed by Google's DeepMind Anglo-US subsidiary with Isomorphic Labs (a subsidiary of Google group’s parent company, Alphabet), AlphaFold3 made headlines in the journal Nature on May 9, 2024 for its ability to predict interaction of protein structures with other molecules like DNA and RNA. This holds immense promise for drug discovery and medical treatments.However, a cloud hangs over this excitement: limited access to the technology.